[1] Aiyappa-Maudsley R, Chalmers A J, Parsons J L. Factors affecting the radiation response in glioblastoma[J]. Neuro-oncology Advances, 2022, 4(1): vdac156. [2] LI Ruiqi, WANG Haihong, LIANG Qing, et al. Radiotherapy for glioblastoma: clinical issues and nanotechnology strategies[J]. Biomaterials Science, 2022, 10(4): 892-908. [3] Kim J, Kang H, Son B, et al. NRBF2-mediated autophagy contributes to metabolite replenishment and radioresistance in glioblastoma[J]. Experimental & Molecular Medicine, 2022, 54(11): 1872-1885. [4] Paolella G, Sposito S, Romanelli A M, et al. Type 2 transglutaminase in coeliac disease: a key player in pathogenesis, diagnosis and therapy[J]. International Journal of Molecular Sciences, 2022, 23(14): 7513. [5] ZHANG Lu, LI Qingya, YANG Jing, et al. Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality[J]. Cancer Communications, 2023, 43(1): 123-149. [6] WANG Yuyan, ZHENG Ni, SUN Tingting, et al. Role of TGM2 in T-cell lymphoblastic lymphoma via regulation of IL-6/JAK/STAT3 signalling[J]. Molecular Medicine Reports, 2022, 25(3): 76. [7] YIN Jinlong, Oh Y T, Kim J Y, et al. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling[J]. Cancer Research, 2017, 77(18): 4973-4984. [8] Vasilev A, Sofi R, Rahman R, et al. Using light for therapy of glioblastoma multiforme (GBM)[J]. Brain Sciences, 2020, 10(2): 75. [9] Minniti G, Niyazi M, Alongi F, et al. Current status and recent advances in reirradiation of glioblastoma[J]. Radiation Oncology (London, England), 2021, 16(1): 36. [10] Zygogianni A, Protopapa M, Kougioumtzopoulou A, et al. From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence[J]. Clinical and Translational Oncology, 2018, 20(8): 989-1003. [11] D'Eletto M, Rossin F, Fedorova O, et al. Transglutaminase type 2 in the regulation of proteostasis[J]. Biological Chemistry, 2019, 400(2): 125-140. [12] Malkomes P, Lunger I, Oppermann E, et al. Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53[J]. Oncogene, 2021, 40(25): 4352-4367. [13] XU Dahai, XU Ning, SUN Liang, et al. TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway[J]. BMC Cancer, 2022, 22(1): 1267. [14] Perillo B, Di Donato M, Pezone A, et al. ROS in cancer therapy: the bright side of the moon[J]. Experimental & Molecular Medicine, 2020, 52(2): 192-203. [15] Lee Y, WANG Q, Seong K M, et al. High-throughput gamma-H2AX assay using imaging flow cytometry[J]. Methods in Molecular Biology, 2023, 2635: 123-134. [16] Vargas J N S, Hamasaki M, Kawabata T, et al. The mechanisms and roles of selective autophagy in mammals[J]. Nature Reviews Molecular Cell Biology, 2023, 24(3): 167-185. [17] Russell R C, GUAN Kunliang. The multifaceted role of autophagy in cancer[J]. The EMBO Journal, 2022, 41(13): e110031. [18] Cassidy L D, Narita M. Autophagy at the intersection of aging, senescence, and cancer[J]. Molecular Oncology, 2022, 16(18): 3259-3275. [19] WEI Jielin, ZHU Kuikui, YANG Zhe, et al. Hypoxia-induced autophagy is involved in radioresistance via HIF1A-Associated beclin-1 in glioblastoma multiforme[J]. Heliyon, 2023, 9(1): e12820. [20] Rakesh R, Priyadharshini L C, Sakthivel K M, et al. Role and regulation of autophagy in cancer[J]. Biochimica Biophysica Acta (BBA) - Molecular Basis of Disease, 2022, 1868(7): 166400. [21] Cayo A, Segovia R, Venturini W, et al. mTOR activity and autophagy in senescent cells, a complex partnership[J]. International Journal of Molecular Sciences, 2021, 22(15): 8149. [22] MA Lan, ZHANG Ruixue, LI Demin, et al. Fluoride regulates chondrocyte proliferation and autophagy via PI3K/AKT/mTOR signaling pathway[J]. Chemico-biological Interactions, 2021, 349: 109659. |